低剂量甲状腺素在风湿病学:一个重新发明的药物
Kushagra Gupta1, Vinod Ravindran2,3
1Joint and Autoimmune Clinic, Gupta Medical Centre, Hisar, Haryana, India.
The journal of the Royal College of Physicians of Edinburgh
|January 10, 2025
概括
低剂量甲状腺素 (LD-MTX) 是一种安全的药物,可以治疗类风湿病,这与人们普遍认为的相反. 目前的证据表明LD-MTX与肝脏或肺纤维化无关,严重的副作用很少出现.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 低剂量甲状腺素 (LD-MTX) 是许多类风湿病的基石疗法.
- 关于LD-MTX安全性的误解仍然存在,通常来自高剂量化疗方案的数据.
- 需要对当前证据进行全面审查,以澄清LD-MTX的安全性.
研究的目的:
- 审查和讨论关于长期低剂量甲状腺素治疗 (LD-MTX) 安全性的最新科学数据.
- 解决和揭穿围绕LD-MTX在风湿病学中的使用常见的神话和误解.
- 为从业者提供基于证据的关于LD-MTX安全性和有效性的观点.
主要方法:
- 对LD-MTX的最新临床数据和研究结果进行系统审查和综合.
- 对调查潜在不良影响的研究进行分析,包括器官毒性和恶性瘤风险.
- 评估有关骨髓抑制,感染和肺部并发症的证据.
主要成果:
- 目前的证据强烈支持LD-MTX的安全性,驳斥了与肝脏和肺纤维化的关联.
- 严重的不良事件,如骨髓抑制和感染风险增加,在慢性LD-MTX使用时不常见.
- 过敏性肺炎是一种罕见的急性毒性,与间歇性肺病不同,MTX甚至可以提供对它的保护. 对皮肤恶性瘤存在轻微担忧,但没有发现其他癌症关联.
结论:
- 长期低剂量甲状腺素 (LD-MTX) 已被证明是治疗类风湿病的安全药物.
- 学术界和临床界应该重新评估LD-MTX,承认其已确定的安全性和有效性.
- 在现代风湿病学实践中,LD-MTX应该被视为一种独特和可靠的治疗剂.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:29Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110
01:17Phase II Reactions: Methylation Reactions
131
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
131